Group 1 - The core viewpoint of the article highlights the significant decline in the stock price of Furuya Medical Technology, which dropped nearly 5% after a more than 13% plunge the previous day, reflecting market concerns over its financial performance [1] - Furuya Medical Technology reported a revenue of $165 million for the first half of 2025, representing a year-on-year decrease of 1.9%, while the profit attributable to the parent company was $6.426 million, down 41.3% year-on-year [1] - The decline in revenue is primarily attributed to challenging market conditions in North America, including high interest rates and weak consumer spending, along with delays in revenue recognition due to regional tensions affecting transportation [1] Group 2 - Excluding the adverse factors in the North American market, Furuya Medical Technology achieved a 7.1% growth in international markets compared to the same period in 2024 [1] - According to Shenwan Hongyuan, the company's performance in North America was significantly impacted by high interest rates and weak consumer demand, which dragged down overall results; however, the international market benefited from a direct sales office layout [1] - The company is positioned as a leading player in the energy source medical aesthetic equipment sector, leveraging its direct sales network to strengthen its advantages in the Asia-Pacific region, with the injection filling business opening a second growth curve [1]
复锐医疗科技再跌近5% 北美市场承压拖累整体业绩 公司上半年纯利同比降四成